Antiangiogenesis: current clinical data and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Neovascularization is crucial for solid tumor growth and metastasis.
• This process is regulated by proangiogenic and antiangiogenic factors, including VEGF, bFGF, and matrix-metalloproteinases.
• Angiogenesis inhibition is a promising therapeutic strategy for malignant tumors, with successful preclinical data.

Purpose of the Study:

• To provide an overview of key angiogenically active substances.
• To review preclinical and clinical data on angiogenesis inhibition in cancer therapy.
• To discuss surrogate markers and future perspectives in targeting tumor neovascularization.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of the roles of key angiogenic factors (VEGF, bFGF, MMPs).
• Examination of preclinical and clinical outcomes of anti-angiogenic therapies.

Main Results:

• Preclinical trials for angiogenesis inhibition have been highly successful.
• Clinical studies show variable response rates, suggesting distinct human angiogenic phenotypes.
• Current understanding of angiogenic cytokine interactions and regulatory systems is incomplete.

Conclusions:

• Angiogenesis inhibition is a vital therapeutic avenue for cancer, but clinical efficacy varies.
• Further research is needed to elucidate complex angiogenic pathways and identify patient subgroups who benefit most.
• Understanding diverse angiogenic phenotypes is critical for optimizing anti-angiogenic cancer treatments.